# US 2025/0375533 A1 · Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375533 A1
- Document ID: US20250375533A1
- Status: Published application
- Kind: A1
- Application number: 19/307,513
- Filed: 2025-08-22
- Published: 2025-12-11
- Earliest claimed: 2022-06-15
- Applicants: Vektor Pharma TF GmbH
- Inventors: Wolfgang Wagner; Bianca Hiestand; Thomas Beckert; Carlos Anjo; Oleksandr Zabudkin; Angelo Colombo
- Web page: https://patentgrep.com/patent/US20250375533A1

## CPC

- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention discloses a transmucosal delivery composition in form of a sublingual orally dispersible film comprising cladribine as active ingredient.

## Claims

### Claim 1

A transmucosal delivery composition in form of a sublingual orally dispersible film comprising cladribine as active ingredient and comprising at least two hydrophilic polymers, wherein the at least two hydrophilic polymers represent at least 20% (w/w), preferably at least 25% (w/w), of the total composition, wherein cladribine is contained in the composition as a cladribine-cyclodextrin complex, wherein the at least two hydrophilic polymers comprise at least one structure forming polymer and at least one binding and/or intercalating polymer, wherein the at least one structure forming polymer is selected from starch polymers, and wherein the at least one binding and/or intercalating polymer is pullulan.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the structure forming polymer has a molecular weight of above 100 000 g/mol and wherein the at least one binding and/or intercalating polymer has a molecular weight of 100 000 g/mol or below.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin, γ-cyclodextrin, hydroxypropyl-γ-cyclodextrin, dimethyl-β-cyclodextrin, randomly methylated β-cyclodextrin, carboxymethyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin.

### Claim 4 (depends on 1)

The composition of claim 1, where cladribine-cyclodextrin complex is comprising cladribine and cyclodextrin with molar ratio from 1:1 to 1:9, preferably 1:1 to 1:3.

### Claim 5 (depends on 1)

The composition of claim 1, comprising the active ingredient, the at least two hydrophilic polymers, and at least one surfactant and/or cosurfactant and at least one plasticizers and optionally further additives, such as taste masking agents, flavoring agents, solubilizers, thickeners, coloring agents, antioxidants, pH modifying agents, vitamins, or mixtures thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the starch polymer is selected from a starch of acorn, arracacha, barley, beans, breadfruit, buckwheat, cassava, chickpea, chestnut, corn, lentil, millet, oat, pea, potato, rice, rye, sago, sorghum, sweet potato, tapioca, wheat and combinations thereof, a pregelatinized starch, a hydroxypropyl starch or a pregelatinized hydroxypropyl starch, a hydroxypropyl pea starch (non- or pregelatinized) said starches being pregelatinized, gelatinized, modified or unmodified.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the at least two hydrophilic polymers are used with a ratio of the first hydrophilic polymer to the second hydrophilic polymer of 95:5 to 5:95 by weight, preferably between 80:20 to 50:50 by weight, more preferably between 70:30 to 60:40 by weight, especially wherein the first hydrophilic polymer is a structure forming polymer and wherein the second hydrophilic polymer is a binding an/or intercalating polymer.

### Claim 8 (depends on 1)

The composition of claim 1, wherein cladribine is incorporated in a 2-hydroxypropyl-8-cyclodextrin complex, hydroxypropyl pea starch, pullulan, glycerol and, optionally, soybean lecithin with at least 70% phosphatidylcholine and/or triacetin.

### Claim 9 (depends on 1)

The composition of claim 1, wherein cladribine is present in amounts of up to 0.01% to 50% by weight of the total composition, preferably 0.1% to 20%, more preferably 1% to 10%.

### Claim 10 (depends on 1)

The composition of claim 1, wherein cladribine is the single effective ingredient.

### Claim 11 (depends on 1)

The composition of claim 1, formulated for treating multiple sclerosis (MS), myasthenia gravis (MG), or neuromyelitis optical spectrum disorders (NMOSD).

### Claim 12 (depends on 1)

A method for producing a transmucosal delivery composition in form of a sublingual orally dispersible film of claim 1, wherein cladribine or cladribine-cyclodextrin complex is mixed with film-forming polymers by stirring with at least 100 rpm for at least 10 min at a temperature of at least 30° C.

### Claim 13

A method of treating multiple sclerosis (MS), myasthenia gravis (MG), or neuromyelitis optical spectrum disorders (NMOSD) comprising administering an effective amount of a transmucosal delivery composition in form of a sublingual orally dispersible film comprising cladribine as active ingredient and comprising at least two hydrophilic polymers, wherein the at least two hydrophilic polymers represent at least 20% (w/w), preferably at least 25% (w/w), of the total composition, wherein cladribine is contained in the composition as a cladribine-cyclodextrin complex, wherein the at least two hydrophilic polymers comprise at least one structure forming polymer and at least one binding and/or intercalating polymer, wherein the at least one structure forming polymer is selected from starch polymers and wherein the at least one binding and/or intercalating polymer is pullulan.
